Advertisement

Advertisement
Skin Cancer
Immunotherapy

Real-World Data Show Survival Benefit for Adjuvant Immunotherapy in Stage III Melanoma

Although ipilimumab is approved as adjuvant therapy for stage III melanoma and has been shown to improve survival when given after complete resection, a little more than one-third of eligible patients received adjuvant immunotherapy after the drug’s approval for this indication, according to early data from a “real-world” analysis presented during the 2020 American Association for Cancer Research (AACR) Virtual Annual Meeting II.

Gastrointestinal Cancer

Lenvatinib Plus Pembrolizumab for Advanced Gastric Cancer

In the Japanese single-center phase II EPOC1706 trial reported in The Lancet Oncology, Kawazoe et al found high objective response among patients with advanced gastric cancer who received the combination of lenvatinib and pembrolizumab as first- or second-line treatment.

 

Multiple Myeloma

Adding Cyclophosphamide to Bortezomib/Dexamethasone in Patients With Multiple Myeloma and Acute Kidney Injury From Cast Nephropathy

In a French trial reported in the Journal of Clinical Oncology, Bridoux et al found adding cyclophosphamide to bortezomib/dexamethasone offered no benefit for renal recovery of patients with multiple myeloma and initial cast nephropathy not requiring dialysis.

 


Advertisement
Survivorship
Issues in Oncology

Patient Factors Associated With Lack of Provider Recommendation for HPV Vaccination in Young Cancer Survivors

In a study reported in the Journal of Clinical Oncology, York et al found that perceived lack of insurance coverage for human papillomavirus (HPV) vaccine, male sex, and decreased parent-survivor communication regarding HPV vaccination were among the factors associated with an increased likelihood that health-care providers did not recommend HPV vaccination in young survivors of childhood cancers.

 

COVID-19

ASCO Coronavirus Resources

As the coronavirus (COVID-19) continues to spread, ASCO is committed to providing the most current information and resources to its members and the larger oncology...

Advertisement




Leukemia
Myelodysplastic Syndromes

Mikkael A. Sekeres, MD, on MDS, CMML, or AML: Pevonedistat and Azacitidine

Hepatobiliary Cancer

SIR 2020 Virtual: Holographic Visualization for Ablation of Liver Tumors

Data from one of the first clinical uses of augmented reality guidance with electromagnetically tracked tools shows that the technology may help doctors quickly, safely, and accurately deliver targeted liver cancer treatments, according to a research abstract presented during a virtual session of...

Advertisement

Impact of Genes on Total Number and Type of Nevi

A study by Duffy et al in the Journal of Investigative Dermatology reported on specific gene variations affecting the number and types of moles on the body and their role in causing skin cancer.  “The goal was to investigate the genetic underpinnings of different mole classes, or...

Head and Neck Cancer

Christopher Nutting, MD, PhD, on Head and Neck Cancer: Dysphagia-Optimized vs Standard IMRT

Kidney Cancer

Study Supports Pembrolizumab Plus Axitinib in Previously Untreated Advanced Renal Cell Carcinoma

Extended analysis of the phase III KEYNOTE-426 study upholds pembrolizumab plus axitinib as a preferred front-line regimen over sunitinib in patients with advanced sporadic renal cell carcinoma.1 These updated results were presented at the ASCO20 Virtual Scientific Program by Elizabeth R. Plimack,...

Solid Tumors

Effect of Radiation Boost to Residual Disease in High-Risk Neuroblastoma

In an analysis from the Children’s Oncology Group (COG) ANBL0532 study reported in the Journal of Clinical Oncology, Liu et al found that a radiotherapy boost to the gross residual tumor in patients with high-risk neuroblastoma did not appear to improve outcomes compared with patients in another...

Gemcitabine/Eribulin in Cisplatin-Ineligible Metastatic Urothelial Carcinoma

In the final analysis from a phase II California Cancer Consortium trial (NCI-9653) reported in the Journal of Clinical Oncology, Sadeghi et al found the combination of gemcitabine and eribulin showed activity in cisplatin-ineligible patients with metastatic urothelial carcinoma. Study Details...

Colorectal Cancer
Immunotherapy

Scott Kopetz, MD, PhD, on Colorectal Cancer: Encorafenib Plus Cetuximab With or Without Binimetinib

Issues in Oncology
Survivorship

Patient Factors Associated With Lack of Provider Recommendation for HPV Vaccination in Young Cancer Survivors

In a study reported in the Journal of Clinical Oncology, York et al found that perceived lack of insurance coverage for human papillomavirus (HPV) vaccine, male sex, and decreased parent-survivor communication regarding HPV vaccination were among the factors associated with an increased likelihood...

Advertisement

Deintensified Chemoradiotherapy for HPV-Associated Oropharyngeal Squamous Cell Carcinoma

In a phase II trial reported in the Journal of Clinical Oncology, Chera et al found that deintensified chemoradiotherapy produced favorable outcomes in human papillomavirus (HPV)-associated oropharyngeal squamous cell carcinoma. Study Details In the multicenter trial, 114 patients were recruited...